Ethylenediamine-Tetra-Acetic (EDTA) Chelation Therapy for Treatment of Atherosclerosis Form
Procedure is not covered
The use of EDTA as a chelating agent to treat atherosclerosis, arteriosclerosis, calcinosis, or similar generalized condition not listed by the FDA as an approved use is not covered. Any such use of EDTA is considered experimental.
Book a walkthrough
Walk through this policy with us
Review how this policy can be converted into cited criteria, prior authorization checks, and operational automation.
Loading available demo times